Planegg
Bavaria
Rigontec
develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases... Read moreRigontec
develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases... Read moreNews
Dec 06, 2019
BioPortfolio
Rigontec: Rigontec GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14122018 Prices from USD $220
Oct 21, 2018
BioPortfolio
Rigontec: Rigontec GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24092018 Prices from USD $250
Oct 19, 2017
BioPortfolio
Rigontec: Rigontec GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12102017 Prices from USD $250
Sep 11, 2017
Market Exclusive
Rigontec: Merck & Co., Inc. (NYSE:MRK) Strengthens Immuno-Oncology Portfolio With Rigontec Acquisition
Sep 09, 2017
Contract Pharma
Rigontec: Merck to Acquire Rigontec
Sep 08, 2017
4-traders
Rigontec: Corporate News Blog - Merck to Acquire German immuno-oncology Company Rigontec
Sep 07, 2017
BioPortfolio
Rigontec: Merck to Acquire Rigontec to Further ImmunoOncology Efforts
Sep 07, 2017
BioPharma-Reporter
Rigontec: Merck boosts cancer pipeline in €464m deal
Sep 06, 2017
Rigontec Blog
Rigontec Blog MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
Sep 06, 2017
PharmaTech
Rigontec: Merck & Co. to Buy German Immuno-Oncology Firm in Nearly $560-Million Dea